Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol

Brachytherapy

Volumn 5, Issue 3, 2006, Pages 152-156

  Gillin, Michael T ^a   Dunning, Bernadine F ^b   Lawton, Colleen A ^c   Foley, W Dennis ^c   Byhardt, Roger W ^c   Morton, Gerard ^d   Baikadi, Madhava ^e   Pisansky, Thomas T ^f   Michalski, Jeff M ^g   Ibbott, Geoffrey ^a   Lopez, Francisco ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e Northeast Radiation Oncology Center   (United States)

^f MAYO CLINIC   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Brachytherapy; Prostate; Transrectal; Ultrasound guided implantation

Indexed keywords

ARTICLE; DOSE CALCULATION; DOSIMETRY; HEALTH CARE QUALITY; HUMAN; IMPLANTATION; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUALITY CONTROL; RADIOLOGIST; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; BRACHYTHERAPY; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RECTUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746058970     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2006.05.004     Document Type: Article

References (10)

1. Blasko J.C., Grimm P.D., and Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 3 (1993) 240-249
2. Blasko J.C., Ragde H., and Grimm P.D. Transperineal vs. guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol 137 (1991) 113-118
3. Blasko J.C., Walker K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 154 (1995) 1096-1099
4. Dose and volume specification for reporting interstitial therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 1997. ICRU Report 58.
5. Williamson J.F., Coursey B.M., DeWerd L.A., et al. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Med Phys 25 (1998) 2269-2270
6. Williamson J.F., Coursey B.M., DeWerd L.A., et al. Guidance to users of Nycomed Amersham and North American Scientific, Inc. I-125 interstitial sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. Med Phys 26 (1999) 570-573
7. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group 43. Med Phys 22 (1995) 209-234
8. Stock R.G., and Stone N.N. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol 41 (2002) 434-439
9. Stock R.G., Stone N.N., Tabert A., et al. A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
10. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230